When is TRAW's latest earnings report released?
The most recent financial report for Traws pharma, inc. (TRAW) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TRAW's short-term business performance and financial health. For the latest updates on TRAW's earnings releases, visit this page regularly.
Where does TRAW fall in the P/E River chart?
According to historical valuation range analysis, Traws pharma, inc. (TRAW)'s current price-to-earnings (P/E) ratio is 1.82, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
How is TRAW's revenue growth?
In the latest financial report, Traws pharma, inc. (TRAW) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does TRAW have?
At the end of the period, Traws pharma, inc. (TRAW) held Total Cash and Cash Equivalents of 3.82M, accounting for 0.36 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does TRAW go with three margins increasing?
In the latest report, Traws pharma, inc. (TRAW) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -7,114.03%%, and net margin of -5,324.56%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TRAW's profit trajectory and future growth potential.
Is TRAW's EPS continuing to grow?
According to the past four quarterly reports, Traws pharma, inc. (TRAW)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.73. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of TRAW?
Traws pharma, inc. (TRAW)'s Free Cash Flow (FCF) for the period is -2.76M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 31.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of TRAW?
The latest valuation data shows Traws pharma, inc. (TRAW) has a Price-To-Earnings (PE) ratio of 1.82 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
